Inspira Technologies OXY BHN Ltd. has completed the regulatory submission of its FDA-cleared INSPIRA ART100 system to the United Arab Emirates Ministry of Health and Prevention (MOHAP). The company expects final approval within days, which would enable commercial entry and potential nationwide deployment of the ART100 system in the Gulf region. This regulatory milestone is a key step in Inspira's global commercialization strategy. No other organizations are noted as recipients of this regulatory review.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inspira Technologies OXY BHN Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-106864), on November 06, 2025, and is solely responsible for the information contained therein.
Comments